HOPA is Proud to Introduce its Pharmacy Peer Network - Available to All

A close-up of a sign

AI-generated content may be incorrect.

You do not have to be a HOPA member to take advantage of this opportunty!

 

Currently Answering Bispecific Antibody Questions

 

As the treatment landscape continues to expand, there is a deep need for information about bispecific antibody therapy across practice settings and sites. That’s why HOPA has identified a group of oncology pharmacy peers ready to help others navigate the following:

 

  • Bispecific implementation 

  • Outpatient observation workflow 

  • Toxicity management 

  • Operational/financial considerations 

  • Education/communication with either patients or the healthcare team

  • Clinical pathways/EHR 

 

Connect with an Expert

 

How does the Network Work? 

A single question is submitted, reviewed, and then answered by a HOPA bispecific SME. Responses will come within 48 business hours via email or virtually. 

 

Who Can Participate?

HOPA Members and non-members receive support from our SMEs! Any questions on how to access the application can be directed to partnerships@hoparx.org. Each interaction is intended to be short term (2-3 days) so our SMEs can continue to provide one-on-one consultations with other cancer care team members. 

 ____________________________________________________________________________________ 

Disclaimer:This peer network is intended to facilitate knowledge sharing among pharmaceutical professionals working in direct patient care roles. The guidance, advice, and other information through this network provided are those of the individual subject matter experts and do not represent official endorsements or recommendations of HOPA. All guidance, advice, or other information provided by individual subject matter experts and is provided at the individual’s discretion and HOPA does not direct, encourage, or influence responses provided by individual subject matter experts. HOPA does not review or approve responses, guidance, or other information provided by individuals who participate in the peer network, including individuals who are HOPA members. Further, all responses, information, and guidance provided by individual subject matter experts is for informational purposes only and is not intended as professional medical or pharmaceutical advice or patient care recommendations. Individual subject matter experts provide anecdotal guidance based on their individual clinical experience. Nothing shared through the peer-to-peer network should be treated as a substitute for an appropriate medical professional’s professional judgment.  

Related News

ISOPP News

Understanding Targeted Therapies and Immunotherapies for Cancer ISOPP's Understanding Targeted Therapies and Immunotherapies for Cancer (UTIC) course - developed in collaboration with the British Oncology Pharmacy Association - is currently available on our e-learning platform.

ISOPP News

New 2026-2027 Secretariat (Incoming) Congratulations!

ISOPP News

Systemic Anti-Cancer Therapy (SACT) and other cytotoxic drugs are critical in cancer treatment but pose serious occupational and environmental risks if not handled properly.